Home / Intelligence / Webinars / Elevating Commercialization in China Part 2: The Key to Pricing and Access Optimization
Available On Demand
In Part 1 of this webinar series, The Path to Launch, we discussed various pathways and innovative programs to accelerate product launch in China. However, launching a product is only half of the battle. Ensuring optimal access to deliver the treatment to more patients is also critical for commercial success.
Join Trinity Life Sciences’ APAC experts for Part 2 as they decode recent key pricing and access dynamics in the China pharmaceutical market and explore what strategies and levers are available to elevate commercial success in China.
Key Webinar Topics
- Latest trends on the pricing and market access landscape in China
- What access pathways/programs are available for innovative products
- Insights from recent launches
Featuring
Wenting Zhang
Director,
Evidence, Value, Access & Pricing
Allen Liu
Senior Consultant & APAC Expert,
Strategic Advisory
Yitong Li
Senior Consultant & APAC Expert,
Strategic Advisory
In Part 3 of this webinar series, our experts will explore:
Part 3: The Winning Commercial Model | Upcoming
Building a model to match China’s changing dynamics
Complete the form below to view the on-demand webinar
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
This webinar will be hosted within the ON24 platform, which requires the usage of Javascript and Cookies. Please see ON24’s Privacy Policy for more information.
Related Intelligence
Webinars
Health Equity in HTA Outcomes: Navigating the New Frontier
April 30, 2025 | 11:00 – 11:45 AM ET / 17:00 – 17:45 CET
Join Value, Access and Pricing experts as they delve into the emerging role of health equity considerations as a differentiator in value narratives for global HTA (Health Technology Assessment) submissions. NICE’s proposed methods update focused on manufacturer-submitted evidence on health inequalities.
Sign Up Now
Webinars
Virtual Demo | HTA Vision with GenAI
Available On Demand
Join Trinity Life Sciences for a virtual demo where value, access and pricing experts Max Hunt and Andreia Ribeiro will demonstrate Trinity HTA Vision, our cloud-based dashboard with GenAI capabilities. It is not enough to know what the health technology assessment (HTA) decisions are and when they are made—with the landscape continually evolving, analogues and future […]
Watch Now
Blog
Learnings to Kick-Start 2025: Health Equity
Health equity continues to be a hot topic in the life sciences industry. ISPOR EU sessions addressed several key questions surrounding the impact of health equity on HTA decision-making, the methodologies that should be employed, and the opportunities and challenges of incorporating health equity into health technology assessment (HTA). Ahead of ISPOR EU, Trinity’s HTA […]
Read More